SPRO
NASDAQSpero Therapeutics Inc.
Price$1.23-0.01 (-1.21%)
01:30 PM07:45 PM
News · 26 weeks39+17%
2026-03-012026-08-23
Mix2790d
- Insider9(33%)
- Other6(22%)
- SEC Filings6(22%)
- Leadership4(15%)
- Earnings2(7%)
Latest news
25 items- SECSpero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form 10-Q filed by Spero Therapeutics Inc.10-Q - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business UpdateEntered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritisClosed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runway into the second half of 2029Appointed Debra Zack, M.D., Ph.D., as Chief Medical OfficerConference call today at 5pm EDT CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, In
- INSIDERChief Medical Officer Zack Debra was granted 162,311 shares (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zack Debra3 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- PRSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that on July 22, 2026, the Compensation Committee of Spero’s Board of Directors approved a grant, to be made on August 3rd, of an aggregate of 324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employee in accordance with Nasdaq Listing
- PRSpero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close. Management will host a conference call and live audio webcast beginning at 5:00 pm EDT to discuss the results and provide a business and pipeline update. To access the call, please dial 1-877-407-0789 (domestic) or 1-201-689-8562 (international) and refer to conference ID 13762082, or click on this link to request
- PRSpero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical OfficerDr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseasesAppointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready third-generation anti-CD40L antibody for IgG4-related disease (IgG4-RD) and other immune-mediated conditions CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer. Dr. Zack will lead Spero’s clinical development strategy and organization
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & RoyaltiesFinancing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt
- PRInnovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyUnder the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001)Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately US$1.1 billion, as well as tiered royalties on net salesSpero plans to initiate a Phase 2 trial for IBI355 in Q2 2027 in IgG4-related disease (IgG4-RD), a serious, chronic fibroinflammatory condition with significant treatment burden and limited therapeutic options Innovent plans to initiate a Phase 2 trial in China by early 2027 for Sjögren's disease (SjD), a
- PRSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyUnder the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately US$1.1 billion, as well as tiered royalties on net salesSpero plans to initiate a Phase 2 trial for SP001 in Q2 2027 in IgG4-related disease (IgG4-RD), a serious, chronic fibroinflammatory condition with significant treatment burden and limited therapeutic options Innovent plans to initiate a Phase 2 trial in China by early 2027 for Sjögren’s disease (SjD), a chronic autoimmu
- PRAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of DirectorsLONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. He is also Chairman of three privately held companies, Micreos Group (Bilthoven, Netherlands), Secura
- PRKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per
- INSIDERDirector Deshpande Milind was granted 10,000 shares, increasing direct ownership by 11% to 101,454 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Tregoning Kathleen was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Smith Cynthia was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Vink Patrick V.J.J. was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Thomas Frank E was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Jackson Scott Thomas was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Pottage John C Jr was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- SECSEC Form 8-K filed by Spero Therapeutics Inc.8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form S-8 filed by Spero Therapeutics Inc.S-8 - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 GSK plc (LSE/NYSE:GSK) and Spero Therapeutics (NASDAQ:SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and o
SPRO FAQ
7 questionsWhat does Spero Therapeutics Inc. do?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary...Where does SPRO stock trade?
Spero Therapeutics Inc. (SPRO) is listed on NASDAQ.What sector and industry is SPRO in?
Spero Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spero Therapeutics Inc. go public?
Spero Therapeutics Inc. (SPRO) completed its IPO in 2017.What are analysts saying about SPRO?
Spero Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $500.00 price target on 2024-12-20. Recent price targets range from $500.00 to $800.00.What companies are similar to SPRO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRO side-by-side with any of them on Quantisnow.How can I track SPRO on Quantisnow?
Quantisnow aggregates Spero Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRO to receive live email and push alerts on every new disclosure.